November 1, 2011
Bookmark and Share  



Welcome to the HCV / HBV Advocate eblast for November 2011. Just a heads up that this month the AASLD Liver Meeting will be taking place in San Francisco and we will be providing onsite coverage and daily news updates. Stay tuned!!


This Month at the HCV and HBV Advocate(s)


Updated HBV Easy B Factsheets

Here's just a few


The HBV Journal Review, by Christine M. Kukka

  • Lab Tests Unable to Detect Hepatitis B in Patients Infected with Genotype G

  • Doctors Unaware HBV Is Spread Primarily Through Heterosexual Activity Among Adults

  • Hepatitis B Vaccine Recommended for Diabetics Under Age 60

  • More Drugs Found to Reactivate Hepatitis B in Patients with Current and Resolved Infections

  • Adefovir-Telbivudine Combination Effective in Lamivudine-Resistant Patients

  • Other Antiviral Combinations Appear Highly Effective in Hard-to-Treat Patients

  • Tenofovir Effective in Treating Patients with Entecavir Resistance

and more.................


Hepatitis C Support Project Training Manual

We are in the process of updating our extremely popular Training Manual, and have posted it in sections both to our Fact Sheet and our Trainer's Page


HBV and HCV Blog: Read about the latest and greatest in the news

Hepatitis Transmission Risk Needs to Be Studied in Nail Salons, Barbershops
October 29

Notes from the Field: Risk Factors for Hepatitis C Virus Infections Among Young Adults --- Massachusetts, 2010
October 29

CDC to Recommend Hepatitis B Vaccination in Diabetes
October 25

Gilead and GlobeImmune Ally to Develop HBV Vaccine for Use in Combination with Viread
October 25

Vertex Starts Global Phase 3b Study to Evaluate the Potential for People with Hepatitis C to Achieve a Viral Cure (SVR) with a Total Treatment Duration of 12 Weeks of INCIVEK™ Combination Therapy
October 24

Boehringer Ingelheim announces new data from hepatitis C virus portfolio
October 22

European studies on risks of hepatocellular carcinoma
October 21

Abbott says hepatitis C combo may be a blockbuster
October 21

Interim Phase IIb Data for Merck's VICTRELIS(TM) (boceprevir) in Patients Coinfected with Chronic Hepatitis C and HIV-1
October 20


New 4 x 6 Tattoo Postcard

Be Sure to check out the latest Tattoo Postcard from the HCV Advocate

To Download this Post Card, click here





Alan Franciscus
Executive Director, Hepatitis C Support Project
Editor-in-Chief, HCV Advocate
Editor-in-Chief, HBV Advocate


**Questions and Comments: Questions and/or comments can be directed to

**To receive the eblast in your email inbox simply send an e-mail to: with nothing in the subject line and the following in the message body: subscribe emailalert. Make sure your email address is all lower case.